PCSK9 and atherosclerosis: Based on the LDL‐C regulatory mechanism of ANGPTL3 independent of LDLR, it is expected to make up for the inadequacy of current PCSK9 inhibitors in lowering LDL‐C and TG to address the residual risk of ASCVD.